Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
下载
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [21] Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (01) : 3 - 19
  • [22] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    LEUKEMIA & LYMPHOMA, 2023, 64 : S170 - S170
  • [23] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
  • [24] Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia
    Hou, Jing-Zhou
    Ryan, Kellie
    Du, Senxi
    Fang, Bruno
    Marks, Stanley
    Page, Ray
    Peng, Eileen
    Szymanski, Keith
    Winters, Sharon
    Le, Hannah
    FUTURE ONCOLOGY, 2021, 17 (35) : 4959 - 4969
  • [25] Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)
    Feinberg, Bruce
    Schenkel, Brad
    McBride, Ali
    Ellis, Lorie
    Radtchenko, Janna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S204 - S205
  • [26] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina P.
    Pinilla-Ibarz, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib
    Jacobs, Ryan
    Wang, Ruibin
    He, Jinghua
    Lu, Xiaoxiao
    Wu, Linda
    Khan, Wasiulla
    Qureshi, Zaina P.
    Levy, Moshe Yair
    BLOOD, 2022, 140 : 8017 - 8018
  • [28] REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST OF CARE AMONG US MEDICARE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING FIRST-LINE IBRUTINIB VS CHEMOIMMUNOTHERAPY
    Huang, Q.
    Emond, B.
    Lafeuille, M. H.
    Gupta, D.
    Lefebvre, P.
    Sundaram, M.
    Mato, A.
    VALUE IN HEALTH, 2020, 23 : S44 - S45
  • [29] Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
    Roeker, Lindsey E.
    DerSarkissian, Maral
    Ryan, Kellie
    Chen, Yan
    Duh, Mei Sheng
    Wahlstrom, Svea K.
    Hakre, Shweta
    Yu, Louise
    Guo, Helen
    Mato, Anthony R.
    BLOOD ADVANCES, 2023, 7 (16) : 4291 - 4301
  • [30] Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab
    Irwin, Debra
    Wilson, Kathleen
    Thompson, Stephen
    Choudhry, Azhar
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 623 - 628
12345